Dexrazoxane as a cardioprotectant in children receiving anthracyclines
about
Chemotherapy-Induced Cardiotoxicity: Pathophysiology and PreventionDexrazoxane for the treatment of chemotherapy-related side effects.Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity.Late effects in childhood cancer survivors: a review with a framing effect bias?Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes.
P2860
Q30399577-93A284DC-C8AA-432F-ABB4-D9ACC58F720AQ34211957-06CAD494-9F9C-492C-8339-21B4992C56B8Q35887269-195C9917-7BBC-4BAA-A193-DE498EED27C1Q37831281-E0A876F3-62DE-4AD3-B9DC-FAF4DFE58A3CQ38264693-4A247198-F226-4566-99A2-AF3CA6C2E589Q38576762-2CD5D64A-BD84-4C2D-9667-170C650E269DQ55387303-E1C3B596-975A-4FCF-B8ED-30723F2EE6AB
P2860
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@ast
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@en
type
label
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@ast
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@en
prefLabel
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@ast
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@en
P2860
P1433
P1476
Dexrazoxane as a cardioprotectant in children receiving anthracyclines
@en
P2093
Dana M Sepe
Jill P Ginsberg
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0162
P50
P577
2010-11-04T00:00:00Z